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Abstract In order to apply structure-based drug design tech-
niques to G protein-coupled receptor complexes, it is essential
to model their 3D structure and to identify regions that are
suitable for selective drug binding. For this purpose, we have
developed and tested a multi-component protocol tomodel the
inactive conformation of the dopamine D2 receptor dimer,
suitable for interaction with homobivalent antagonists. Our
approach was based on protein–protein docking, applying
the Rosetta software to obtain populations of dimers as present
inmembranes with all the main possible interfaces. Consensus
scoring based on the values and frequencies of best interfaces
regarding four scoring parameters, Rosetta interface score,
interface area, free energy of binding and energy of hydrogen
bond interactions indicated that the best scored dimer model
possesses a TM4–TM5–TM7–TM1 interface, which is in
agreement with experimental data. This model was used to
study interactions of the previously published dopamine
D2 receptor homobivalent antagonists based on cloza-
pine,1,4-disubstituted aromatic piperidines/piperazines and
arylamidoalkyl substituted phenylpiperazine pharmacophores.
It was found that the homobivalent antagonists stabilize the
receptor-inactive conformation by maintaining the ionic lock
interaction, and change the dimer interface by disrupting a set
of hydrogen bonds andmaintaining water- and ligand-mediated
hydrogen bonds in the extracellular and intracellular part of the
interface.
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Introduction
Dopamine receptors can be categorized into five different sub-
types (namely D1 to D5), which are all members of the G
protein-coupled receptor (GPCR) superfamily. These recep-
tors can be further classified into D1-like (D1 and D5) and
D2-like (D2, D3 and D4) receptors depending on activation
or inhibition of the second messenger cyclic adenosine
monophosphate (cAMP), respectively [1, 2]. Dopamine re-
ceptors are implicated in many disease states, including
Parkinson’s disease, restless legs syndrome, sexual dysfunc-
tion, dementia, depression, bipolar disorder, Huntington’s dis-
ease and schizophrenia. Consequently, drug discovery has
been focusing on targeting the dopaminergic system for over
half a century, resulting in a range of dopaminergic pro-drugs,
agonists, antagonists, and enzyme inhibitors presently on the
market [3].
Traditionally, research in academia and industry has been
focusing on the discovery and development of drugs targeting
the orthosteric pocket of a receptor monomer. The function of
GPCRs is classically described by the ternary complex model
as the interplay of three basic components: a receptor
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monomer, an agonist and a G protein. According to this mod-
el, receptor activation results from an interaction with an ago-
nist, which translates into the activation of a particular G pro-
tein in the intracellular compartment that, in turn, is able to
initiate particular signaling cascades. The growing body of
experimental evidence onGPCR functioning has revealed that
GPCR signaling can be modulated in ways much more com-
plicated than those contemplated in the ternary complex mod-
el, which has led to a paradigm shift in GPCR oriented drug
discovery [4]. In particular, the accumulation of experimental
and computational evidence from cross-linking experiments,
BRET and FRET studies [5] and coarse-grained molecular
dynamics simulations reporting negative and positive
cooperativity, has suggested the possibility that GPCRs may
be capable of oligomerization [6, 7]. In recent years, both
homo- and heterodimerization have been described for an
increasing number of GPCRs, and, in some cases, these asso-
ciations have been related to particular functional outcomes
[8, 9]. For this reason, GPCR oligomers have also been re-
ported as potential drug targets, which, due to their restricted
tissue distribution, could provide a new source of drug spec-
ificity. Despite the increasing amount of functional interac-
tions that have been described between dimers, the develop-
ment of drugs with the ability to target receptor oligomers is
still very challenging. Therefore, a deeper characterization of
the basis of receptor dimerization and of its impact on signal-
ing, together with the development of original treatment strat-
egies, will be necessary for the pharmacological exploitation
of this phenomenon [10].
As a consequence of the paradigm shift in GPCR-oriented
drug discovery, the scientific community has gained interest in
the development of novel types of molecules including homo-
and heterobivalent ligands. These modern concepts result in
new challenges for molecular modelers to provide medicinal
chemists with appropriate receptor models of homo- and
hetero-dimers and higher oligomers, which allow accurate
predictions of possible binding modes of these novel types
of molecules.
Molecular modeling approaches used to study GPCR olig-
omerization can be categorized into sequence-based and
structure-based methods [11]. The first group is based on the
GPCR sequence analysis performed in order to detect evolu-
tionary changes in GPCR interfaces. However, to use
structure-based drug design approaches for GPCR dimers
and oligomers, it is necessary to model their 3D structure.
Structure-based approaches involve protein–protein docking
and molecular dynamics techniques as well as electrostatics
analysis with adaptive Poisson-Boltzmann solver (APBS) and
normal mode analysis (NMA). Previously, we elaborated a
multi-component protocol [12] for modeling GPCR dimers
that is based on protein–protein docking with Rosetta software
[13]. In this protocol, populations of dimers compatible with
membrane integration are generated, taking into account all
possible interfaces. The method involves external scoring (as
protein–protein docking itself fails in case of GPCR dimers
[14]), followed by consensus scoring of the resulting dimers
according to (1) Rosetta total score, (2) Rosetta interface
score, (3) surface of the dimer interface, (4) polar contribution
to the dimer interface, (5) fractal dimension of the dimer in-
terface [15, 16], (6) evolutionary conservation score [17, 18],
(7) shape complementarity, (8) electrostatic complementarity,
(9) potential energy [19], (10) free energy of binding [19], and
(11) energy of hydrogen bond interactions [12, 20]. The pro-
tocol was tested by prediction of the dimer structure of GPCR
dimers with existing X-ray structures, and it was concluded
from these studies that the Rosetta interface score, interface
area, free energy of binding and the energy of hydrogen bond
interactions were the best performing scoring factors [12].
Dopamine D2 receptor homodimers might be particularly
important for the pathomechanism of Parkinson’s disease and
schizophrenia, and may serve as attractive targets for
antiparkinsonian drugs and antipsychotics. In our previous
study based on experimental data, we constructed a D2 recep-
tor dimer model suitable for interaction with agonists, and
studied its interactions with homobivalent ropinirole-based
agonists [21]. The current study was focused on the molecular
modeling of a dopamine D2 receptor homodimer suitable for
interactions with antagonists using our protocol, and investi-
gating the receptor’s interactions with published examples of
homobivalent antagonists. Homobivalent ligands are
molecules containing two entities of the same pharmacophore
separated by a spacer unit (Fig. 1). Homobivalent ligands are
interesting pharmacological tools for the probing of
homodimers; however, their use as drugs is potentially limited
due to their high molecular mass, lipohilicity and polar
surface area. The work presented includes the previously
published dopamine D2 receptor homobivalent antagonists
based on clozapine [22], 1,4-disubstituted aromatic
piperidines/piperazines [23], and arylamidoalkyl substituted
phenylpiperazine [24] pharmacophores. We studied interac-
tions of homobivalent antagonists with a dopamine D2 recep-




The homology model of the human dopamine D2 receptor
(P14416) in the inactive conformation and in complex with
the antagonist eticlopride were constructed using homology
modeling with Modeller 9.10 [25] as described previously
[26, 27]. The X-ray structure of the dopamine D3 receptor in
complex with the antagonist eticlopride (PDB ID: 3PBL) [28]
was used as a template. Multiple sequence alignment of 50
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rhodopsin-like GPCRswas performedwith the GPCRmodule
of MOEMolecular environment [29]. Manual refinement was
used in particular to satisfy the disulfide bridges, which were
not found automatically by the software. The dopamine D2
receptor model was constructed without the N-terminus (the
first 36 residues were omitted, the model starts with Tyr37),
and without intracellular loop 3 (ICL3, residues Arg217–
Lys362 were pmitted). A total of 100 homology models of
the D2 receptor in complex with eticlopride were generated,
and subsequently assessed by the Modeller objective function
and Discrete Optimized Protein Energy profiles [30]. The best
model was subjected to quality assessments using the MOE
Molecular Environment module for Ramachandran plots [29].
Initial set of dimers
We constructed an initial set of 144 plausible dimer interfaces
by rotating one monomer around the other. This task was
performed by creating a tcl script for VMD [31] as previously
described [12]. The resulting set of dimers was compatible
with membrane integration as the starting dimer was
membrane-compatible and only rotation around z-axis was
allowed.
Protein–protein docking with Rosetta
Protein–protein docking with Rosetta [13] was used to obtain
10 dimers with each interface, resulting in 1440 final dimers.
In order to obtain dimers compatible with membrane integra-
tion (as in input dimers were generated as above) protein–
protein docking was performed in ‘refine only’ mode.
Otherwise, default parameters were used.
Details of scoring parameters
As previously suggested, we used four scoring parameters to
assess the obtained set of dimers: Rosetta interface score, in-
terface area, free energy of binding, and energy of hydrogen
bond interactions [12]. The Rosetta interface score is one of
the recorded parameters after protein–protein docking with
Rosetta [13]. The interface area was calculated using VMD
[31], being the difference of the sum of the molecular surfaces
of two monomeric TM domains and the molecular surface of
the TM domains in the dimer, as previously reported [12]. The
free energy of binding, and the energy of hydrogen bond in-
teractions (fraction of free energy of binding caused by hydro-
gen bonds), were calculated with Rosetta interface analyzer
[13] as previously described [12]. Two methods of consensus
scoring were used: (1) average scores of the 100 best scored
dimers with respect to each interface, and (2) frequencies of
interfaces among the 100 best scored dimers. Before consen-
sus scoring was performed, the parameters were normalized to
adopt values from 0 to 1.
Minimization of the final dimer model
Before using for molecular docking of bivalent ligands the
final homodimer model was minimized in order to adjust side
chain conformations of the residues forming the interface
using MOE Molecular environment [29]. Only side chains
of the interface residues were subjected to minimization.
Compound preparation
The investigated compounds (reference ligands chlorprothixene
and olanzapine and compounds 1a-1f, 2a-2 g, 3a-3 g, 4a-4i and
5a-5n) were modelled using the LigPrep protocol from
Schrödinger Suite [32]. The Epik module was used for different
protonation states of the ligands at physiological pH. [33]. The
compounds were further optimized with the Wavefunction
Spartan10 software [34]. The procedure involved geometry op-
timization performed with B3LYP DFT using the 6-31G(d,p)
basis set.
Molecular docking
First, the complexes of the dopamine D2 receptor with
chlorprothixene or olanzapine were constructed with Glide/
induced-fit docking [35, 36] using the software Schrödinger
suite. The grid was generated with default settings. The initial
position of bivalent ligands was found manually and refined
using Glide.
Molecular dynamics
Molecular dynamics studies of ligand–receptor complexes
were performed using Desmond v. 3.0.3.1 [37] and OPLS
force field as described previously [38, 39]. The complexes
were inserted into the POPC (1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine) membrane, hydrated, and ions
were added to neutralize protein charges and then to the
reaching of a concentration of 0.15 M NaCl. The size of the
simulation boxes was approximately 85 Å×92 Å×128 Å.
The complexes were minimized and subjected to MD first in
the NVTensemble (constant number of particles, volume, and
temperature) ensemble for 1 ns and then in NPT ensemble
Fig. 1 Schematic representation of a homobivalent ligand
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(constant number of particles, pressure, and temperature) for
20 ns with the restrictions on the protein backbone in each
case [40]. The production run was performed in NPT ensem-
ble with no restrictions for 50 ns. Analysis of molecular dy-




The obtained homology model of the D2 receptor in the inac-
tive conformation has been described in detail previously
[26, 27]. The sequence identity between the template and the
target was 79 %, and the sequence similarity was 90 %. The
model possesses two disulfide bridges, one between Cys107
and Cys182, and the other between Cys399 and Cys401
[26, 27].
Modeling D2 receptor homodimer in the inactive
conformation
We demonstrated previously that protein–protein docking
methodology should be used with great care for modeling
dimers and oligomers of GPCRs and, probably, the successful
building of such complexes would require the support of ex-
perimental or sequence-based data about the residues involved
in the interface [14]. We showed that the docking success is
promoted by high symmetry order of the complex whereas
other parameters, such as the hydrophobic/hydrophilic char-
acter of the interface turned out to have no correlation with the
success of protein–protein docking [14]. In order to enhance
the protein–protein docking performance for modeling GPCR
dimers, we elaborated a protocol based on protein–protein
docking with Rosetta supported by external scoring [12]. We
applied this protocol to model D2 receptor dimers in the
inactive conformation. A population of 1440 dimers with all
possible interfaces was scored according to Rosetta interface
score, interface area, free energy of binding, and hydrogen
bond energy. Two methods of scoring were used, based
on parameter values and best models frequency (see
Computational methods). The scoring based on normalized
parameter values and on best model frequency is presented
in Fig. S1 and Fig. S2 in the Supplementary Information,
respectively. In addition, Table 1 gives a summary of the best
scored interfaces according to both approaches.
The consensus scoring for both parameter values and fre-
quencies is shown in Fig. 2 and summarized in Table 1. The
TM2–TM3–TM2–TM3 interface was disregarded as it has
never been reported for any GPCR as TM2 and TM3 helices
are involved in orthosteric ligand binding and/or allosteric
modulation by sodium ions [41]. Thus, the dimer model with
the interface formed by transmembrane helices TM4–TM5–
TM7–TM1 was selected for further studies. This result is sup-
ported by high scoring results of both TM4–TM5 and TM7–
TM1 interfaces partnered with other interfaces (see Fig. S1–
S2 and Fig. 2) as well as by recent experimental data for a
close homolog of the D2 receptor, namely the D3 receptor
dimer [42]. Marsango et al. [42] used molecular modeling,
mutagenesis and analysis of inactive state receptor crystal
structures to indicate that D3 monomers can interact with each
other via at least two distinct interfaces: the first comprising
residues from transmembrane domains TM1 and TM2 along
with those from TM7, and a second involving transmembrane
domains TM4 and TM5. Moreover, Guitart et al. [43] also
reported that the D1 receptor TM5 peptide was also able to
reduce D1–D1 receptor complementation. This implies, ac-
cording to the authors, [43] that D1 receptor TM5 forms part
of the D1–D3 receptor heteromer, and D1–D1 receptor
homomer interfaces, which can be also extended to the
D2–D2 receptor homdimer.
Structure of the dopamine D2 receptor homodimer
The structure of the final dopamine D2 receptor dimer is pre-
sented in Fig. 3. The interface is stabilized by the hydrogen
bond between the main chain of Tyr37 (N terminus) and the
side chain of Tyr 5.42 (Ballesteros-Weinstein nomenclature
[44]) from the other subunit. The following residues form
the interface (as indicated by PISA online tool [45]): from
subunit A: Leu 3.41, Tyr 3.51, Ala 3.55, Met138 (ICL1),
Pro139 (ICL1), Met140 (ICL1), Leu141 (ICL1), Ile 4.48,
Leu 4.52, Ala 5.38, Val 5.41, Tyr 5.42, Ile 5.45, Val 5.46,
Val 5.49, Ile 5.52, Thr 5.54, Leu 5.56, Ile 5.59, Lys 5.60, Ile
5.63, Val 5.64; and from subunit B: Tyr37 (N terminus), Ala38
(N terminus), Thr39 (N terminus), Leu 1.38, Leu 1.41, Phe
1.48, Val 7.32, Leu 7.33, Ala 7.36, Trp 7.39, Leu 7.40, Val
7.43, Val 7.48, Ile 7.51, Thr 7.54, Thr 7.55, Arg 8.51, Leu
8.55, Leu 8.58, His442 (C terminus), and Cys443 (C termi-
nus). This is in agreement with experimental data as it has
been indicated that ICL3 from one subunit and the C terminus
from the other subunit participate in the dopamine dimer for-
mation, and are involved in electrostatic interactions [46].
Although the model was constructed without ICL3, it indi-
cates the involvement of the C terminus in the homodimer
formation.
The constructed model represents one possibility of a D2
receptor homodimer structure; another model of the active
state with a TM4–TM5–TM4–TM5 interface was proposed
earlier by us [21] and Durdagi et al. [47] for both the active
and inactive state. These two models differ in the distance
between two orthosteric sites and the orthosteric to the allo-
steric sites, which are slightly greater in the model with the
TM4–TM5–TM7–TM1 interface (Table 2). The hypothesis
about the possible existence of multiple GPCR interfaces
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Table 1 Summary of best scored
interfaces for the dopamine D2
receptor homodimer model
Method of scoring Scoring parameter (Figure) Best scored interfaces
Normalized parameter values Rosetta interface score (Fig. S1a) (1) TM3-TM4-TM7-TM1
(2) TM2-TM3-TM2-TM3
(3) TM4-TM5-TM7-TM1
Interface area (Fig. S1b) (1) TM2-TM3-TM2-TM3
(2) TM4-TM5-TM4-TM5
(3) TM4-TM5-TM7-TM1
Free energy of binding (Fig. S1c) (1) TM2-TM3-TM2-TM3
(2) TM3-TM4-TM7-TM1
(3) TM5-TM6-TM5-TM6
Hydrogen bond energy (Fig. S1d) (1) TM3-TM4-TM3-TM4
(2) TM5-TM6-TM5-TM6
(3) TM4-TM5-TM5-TM6
Consensus scoring (Fig. 2a) (1) TM2-TM3-TM2-TM3
(2) TM4-TM5-TM7-TM1
(3) TM4-TM5-TM4-TM5
Best model frequencies Rosetta interface score (Fig. S2a) (1) TM4-TM5-TM7-TM1
(2) TM3-TM4-TM5-TM6
(3) TM3-TM4-TM4-TM5
Interface area (Fig. S2b) (1) TM4-TM5-TM7-TM1
(2) TM3-TM4-TM4-TM5
(3) TM4-TM5-TM6-TM7
Free energy of binding (Fig. S2c) (1) TM4-TM5-TM7-TM1
(2) TM3-TM4-TM7-TM1
(3) TM3-TM4-TM5-TM6
Hydrogen bond energy (Fig. S2d) (1) TM4-TM5-TM5-TM6
(2) TM3-TM4-TM4-TM5
(3) TM3-TM4-TM7-TM1
Consensus scoring (Fig. 2b) (1) TM4-TM5-TM7-TM1
(2) TM3-TM4-TM4-TM5
(3) TM3-TM4-TM7-TM1
Fig. 2 a Consensus scoring of normalized values, and b frequencies of
best interfaces. Scoring was performed for 28 interfaces (x-axis) labeled
according to transmembrane (TM) helices forming the interface, e.g., 12_
12 for the interface formed by TM1 and TM2 from one monomer, and
TM1 and TM2 from the other monomer
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has been supported recently by the demonstration that the
dimer life-time is even shorter than previously thought [48].
Single-molecule imaging made it possible to determine the 2D
monomer-dimer equilibrium constant, the dimer dissociation
rate constant (typically∼10 s−1), and the formation rate con-
stant, which has demonstrated that GPCRs exist in dynamic
equilibria between monomers and dimers [48]. Within 1 s,
GPCRs typically undergo several cycles of monomer and ho-
modimer formation with different interfaces, supporting the
hypothesis of multiple oligomerization interfaces [48]. Thus,
both models, with TM4–TM5–TM4–TM5 and TM4–TM5–
TM7–TM1 represent two equally probable dopamine D2 re-
ceptor homodimer assemblies. Obviously, the interface does
not depend on the dimer activation state and, in principle, both
kinds of models can be used for molecular docking of bivalent
agonists and antagonists on condition that they are built using
receptor monomer models in the active or inactive conforma-
tion. Thus, in order to dock bivalent agonists to the dimer
model with the TM4–TM5–TM7–TM1 interface, the model
has to be reconstructed using receptor monomer models in the
active conformation. The same applies to our previously con-
structed dimer model with the TM4–TM5–TM4–TM5 inter-
face: in order to dock bivalent antagonists to this model, the
model has to be rebuilt by applying receptor monomer models
in the inactive conformation.
Molecular docking of the reference ligands
Two reference ligands, chlorprothixene and olanzapine, were
docked to the model of the dopamine D2 receptor homodimer
receptor using the SP (standard precision) protocol of Glide
from the Schrödinger suite software. The docking poses were
refined using the induced-fit docking approach in the
Schrödinger suite. The final docking poses were identified
by visual inspection among the poses, where the protonatable
nitrogen atom of the ligands interactedwith the conserved Asp
3.32 of the receptors. The docking poses of chlorprothixene
and olanzapine are shown in Fig. 4. It can be seen that a key
interaction for both ligands is an electrostatic interaction be-
tween the protonatable nitrogen atom of the ligand and Asp
3.32. Moreover, Trp 6.48, Phe 6.61 and His 6.55 were also
found to be important for the binding of both ligands.
The studied bivalent ligands
The studied bivalent ligands are based on clozapine [22], 1,4-
disubstituted aromatic piperidines/piperazines [23], and
arylamidoalkyl substituted phenylpiperazine [24]
pharmacophores, which are presented in Figs. 5, 6 and 7.
The reported biological activities of these ligands are given
in Table 3.
Molecular docking of bivalent ligands
Bivalent ligands 1a–1f, 2a–2g, 3a–3g, 4a–4i and 5a–5n were
docked into the dopamine D2 receptor homodimer model.
None of the molecular docking software used (Surflex [49],
Molegro [50], Glide [36]) was able to identify a correct
docking pose of the bivalent ligand automatically, thus the
initial ligand position was found manually and refined with
Glide. In all cases, the docking poses selected included elec-
trostatic interaction of the protonated nitrogen atom(s) of the
ligand with Asp 3.32 from at least one monomer.
The first group of studied compounds involves homobivalent
ligands based on clozapine 1a–1f, 2a–2 g and 3a–3 g [22]. These
Fig. 3 Structure of the final model of the dopamine D2 receptor
homodimer. Transmembrane helices (TMs) are shown in ribbon
representation, colored in spectrum mode and labeled with their
respective numbers
Table 2 Distances between








Orthosteric-orthosteric in different protomers through the membrane region ~38 ~34
Orthosteric-orthosteric in different protomers without crossing a membrane
region
~60-65 ~50-60
Orthosteric-allosteric in one protomer ~18 ~18
Orthosteric-allosteric in different protomers across the homodimer ~40-45 ~30-40
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ligand groups differ in their linker attachment point. Compounds
1a–1f and 2a–2 g have the N5 nitrogen atom as the linker at-
tachment point as it has been suggested that clozapine modifica-
tions at this positionmay reduce agranulocytosis, which is awell-
known side effect of clozapine [22]. Compounds 1a–1f are di-
rectly acylated at the N5 nitrogen atom, whereas compounds 2a–
2g bear a hydrazine moiety at this position. Compounds 3a–3g
have the linker attached at the distant N4′-piperazine nitrogen
atom.Molecular docking indicated thatmarginal activity of com-
pounds 1a–1f and 2a–2g in comparison to clozapine may be
caused by unfavorable conformation of these compounds caused
by the linker attachment point, which makes it difficult for the
ligand to interact with the conserved Asp 3.32, and to adopt well
to the orthosteric pocket. Indeed, only very few poses fulfilling
the requirement of this interaction were obtained for compounds
1a–1f and 2a–2g. This is in line with reports that only certain
substituents at the N5 position of clozapine are tolerated [22, 51].
However Su et al. [52] reported that the N5-clozapine derivative
with a relatively large substituent (o-TolSO2) displayed dopa-
mine D2 receptor affinity of 63 nM, whereas the affinity of clo-
zapine to this receptor is 208 nM. Thus, this effect is the least
important for the smallest compounds 1a, 2a and 2b (linker
length 6–8 atoms) that can adopt a conformation able to interact
within one monomer in the homodimer. Examples of docking
poses for compounds 1a and 2a are shown in Fig. 8. It can be
seen that both ligands bind in the orthosteric site of onemonomer
and are large enough to direct to another monomer, but are not
able to interact with either the allosteric or the orthosteric site of
the other monomer. Instead, ligand 1a interacts with the allosteric
site within one monomer so such compounds might behave as
bitopic ligands. Ligands of medium size like 1d (linker length of
14 atoms) may direct towards the allosteric site of the other
monomer (Fig. 8c). Their lack of potency can be attributed
to the hampered interactionwithAsp 3.32, and amolecular shape
that does not fit the receptor orthosteric pocket. In contrast, com-
pounds 3a–3g all displayed better potency than clozapine and
spacer-dependent inhibitory activity [22]. The best potency and
dopamine D2 receptor affinity was observed for compounds 3b
and 3c, with 16- and 18-atom spacers, respectively. Molecular
docking indicated that the enhanced affinity of these compounds
may be caused by the fact that this spacer length enables favor-
able interactions of the ligands with the orthosteric site of one
monomer, and the allosteric site of the other monomer, as we
reported previously for ropinirole-based bivalent ligands [21].
Compound 3a is slightly too small to target both sites, whereas
compounds 3d–3g are too extended for an orthosteric–allosteric
mode of interaction but still too small to target the orthosteric
pockets of both monomers without crossing the membrane,
which is theoretically possible but not favorable for steric
reasons.
Fig. 4 Reference ligands chlorprothixene (a) and olanzapine (b) docked
into the orthosteric site of the dopamine D2 receptor homology model.
Key interactions of the protonatable nitrogen atom of the ligands with the
conserved Asp 3.32 (presented as sticks) are shown as red dashed lines.
Other important residues, Trp 6.48, Phe 6.51 and His 6.55 are also shown
as sticks. TMs are colored in spectrum mode. Hydrogen atoms are not
shown for clarity
Fig. 5 Clozapine-based homobivalent ligands 1a–1f, 2a–2 g and 3a–3 g
[22]
J Mol Model (2016) 22: 3065 Page 7 of 14 203
The phenomenon that bivalent ligands occupy two
orthosteric sites within the receptor dimer is controversial.
Although bivalent ligands are designed to interact with both
orthosteric sites, we demonstrated previously that ropinirole-
based bivalent ligands are, in general, too small for such a
binding mode and instead they may interact with the
orthosteric site in one monomer and the allosteric site in the
other monomer [21]. 1,4-Disubstituted aromatic piperidine/
piperazine-based homobivalent ligands 4a–4iwere previously
studied experimentally regarding their binding modes [23].
The 1,4-disubstituted aromatic piperazines 4a–4i exhibited a
change in the Hill slope in binding experiments for the
homobivalent ligand compared to the monovalent ligands
[23]. Gmeiner and co-workers postulated that a Hill slope of
2 indicates occupancy of both orthosteric sites of a D2R ho-
modimer [23]. Based on the mathematical model, the steep-
ening of the curve is the consequence of one bivalent ligand
causing the displacement of two equivalents of the
radioligand. It was claimed that these compounds are capable
of interacting with two orthosteric sites, and that no allosteric
modulation effect is connected with compound 4b. However,
the 1,4-disubstituted aromatic homobivalent piperazines 4a-4i
with the increased Hill slope did not display any improved
affinity for the D2R compared to the monovalent counterparts,
as would be predicted by the occupancy of two identical
orthosteric ligands within a homodimer [23]. The interaction
with two orthosteric sites is possible for these compounds only
with the assumption that the compounds cross the membrane
as in the case of compound 4c (Fig. 9a). These results are in
accordance with our earlier results for bivalent agonists of the
D2 receptor [21]. The best potency of compounds 4e, 4f and 4i
can be attributed to a favorable linker length, enabling
orthosteric–allosteric interactions within two receptor
monomers.
In contrast, the clozapine homobivalent ligands 1a–1f, 2a–
2 g and 3a–3 g, showed no change in the Hill Slope, but a
significant increase in binding affinity (75- and 79-fold) and
functional potency (6- and 7-fold) [22]. In both cases, the
docking of the homobivalent ligands into our D2R dimer mod-
el indicates that it is rather unlikely that both orthosteric sites
Fig. 7 Arylamidoalkyl
substituted phenylpiperazines-




based homobivalent ligands 4a–
4i [23]
203 Page 8 of 14 J Mol Model (2016) 22: 203
can be engaged concurrently by one homobivalent ligand.
The linker length of the synthesized ligands in both groups
allows the homobivalent ligands only to interact at both
orthosteric sites in a favourable binding mode when crossing
the GPCR membrane. However, a binding mode including
crossing of the membrane, although theoretically possible, is
unlikely to occur in a biological system due to steric consid-
erations. Therefore, our study provides further evidence that
Table 3 Biological activity of the
investigated compounds towards
D2 dopamine receptor. NA Not
available, NAP not applicable
Compound number Spacer length Affinity, Ki (nM) Potency
IC50 (nM)
Reference
1a 8 NA 2662 [22]
1b 10 NA >10,000 [22]
1c 12 NA >10,000 [22]
1d 14 NA >10,000 [22]
1e 18 NA >10,000 [22]
1f 20 NA >10,000 [22]
2a 6 NA 2078 [22]
2b 8 NA 2440 [22]
2c 10 NA >10,000 [22]
2d 12 NA >10,000 [22]
2e 14 NA >10,000 [22]
2f 18 NA >10,000 [22]
2 g 20 NA >10,000 [22]
3a 14 3.6 87 [22]
3b 16 1.41 23 [22]
3c 18 1.35 44 [22]
3d 20 NA 1119 [22]
3e 22 NA 11,000 [22]
3f 26 269 7800 [22]
3 g 28 NA >10,000 [22]
4a 18 25 NA [23]
4b 22 41 NA [23]
4c 24 17 NA [23]
4d 26 8.2 NA [23]
4e 18 3.4 NA [23]
4f 22 3.7 NA [23]
4 g 25 6.2 NA [23]
4 h 22 17 NA [23]
4i 22 1.1 NA [23]
5a NAP 6.4 NA [24]
5b NAP 1.8 NA [24]
5c NAP 19 NA [24]
5d NAP 11 NA [24]
5e NAP 32 NA [24]
5f NAP 15 NA [24]
5 g NAP 20 NA [24]
5 h NAP 25 NA [24]
5i NAP 66 NA [24]
5j NAP 16 NA [24]
5 k NAP 2.7 NA [24]
5 l NAP 0.59 NA [24]
5 m NAP 3.9 NA [24]
5n NAP 4.6 NA [24]
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these ligands potentially show a bivalent (engaging of both
orthosteric and allosteric binding sites) binding mode either
within one protomer or across a homodimer. The change in the
Hill slope to a steeper gradient that was observed for the 1,4-
Fig. 8 a, bDocking poses for the smallest ligands 1a (a) and 2a (b), and
c a medium size ligand 1d (the compound directs toward the allosteric site
in the second monomer). Protein shown in ribbon representation, colored
in spectrum mode. Ligands shown as spheres with magenta carbon
atoms. 2D interaction maps are also presented
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disubstituted aromatic piperazines, may be explained by pos-
itive cooperativity between receptor protomers within a recep-
tor homodimer as our study indicates that is unlikely for these
ligands to occupy both orthosteric sites simultaneously [21].
In case of compounds 5a–5n, it was found that compounds
5a–5i are capable of allosteric–orthosteric interactions where-
as bigger compounds 5j–5n are able to interact with both
orthosteric sites (Fig. 9b). This is reflected by significantly
better potency of compounds 5j–5n in comparison to 5a–5i.
Molecular dynamics
Molecular dynamics of all the ligand–receptor complexes in
the POPC membrane was performed. The ligand–receptor
complexes were in general stable (complex RMSD below
4 Å), and is presented for all the complexes in the
Supporting Information. The effect of bivalent antagonists
on the inactive receptor conformation was investigated (i.e.,
the change in distance between the ionic lock residues during
50 ns simulations). In the inactive state of family A GPCRs,
there is a strong intramolecular interaction between residues
Asp 3.49 and Arg 3.50 of the conserved (D/E)RY motif in
TM3, and residues Glu 6.30 and Thr 6.34 in TM6 [53]. It was
found that bivalent antagonists stabilize the receptor inactive
conformation (Fig. 10). Moreover, it was determined that bi-
valent antagonists change the dopamine D2 receptor dimer
interface by disrupting a set of hydrogen bonds that are weak-
er than in the apo form (Fig. 11). In particular, the following
intersubunit hydrogen bonds are disrupted: Tyr37 (N termi-
nus) – Tyr 5.42, Leu 5.65 – Lys 8.52, Arg145 (IL1) – Cys443
(C terminus), Fig. 11. However, the dimer interface is stabi-
lized in a different way in the presence of bivalent ligands
thanks to the increased number of water-mediated hydrogen
bonds involving the ligands (in the extracellular and also
Fig. 9 Different types of poses for bigger ligands. a Compound 4c
crosses the membrane to direct the other monomer (improbable pose). b
Compound 5j interacts with two orthosteric sites (a probable pose).
Protein shown in ribbon representation, colored in spectrum mode.
Ligands shown as spheres with magenta carbon atoms. 2D interaction
maps also presented
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intracellular part of the interface) in comparison to the dimer
apo form.
In order to identify the changes in the D2 receptor homodi-
mer conformation in the apo form and in complex with a
bivalent ligand, the respective protein structures after 50 ns
molecular dynamics simulations were superimposed (Fig. 12).
The RMSD between the two structures was 4.61 Å. In the case
of the monomer contributing TM7–TM1 to the interface (the
Fig. 11a–f Destabilization of the
homodimer interface by bivalent
antagonist 5j. a, b The distance
between Tyr37 and Tyr 5.42 in the
apo form (a) and in the complex
with the ligand (b). c, d The
distance between Arg145 and
Cys443 in the apo form (d) and in
the complexwith the ligand (d). e,
f The distance between Leu 5.65
and Lys 8.52 in the apo form (e)
and in the complex with the
ligand (f)
Fig. 10a–d Changes between
residues Arg 3.50 and Glu 6.30
forming ionic lock distances
during 50-ns simulations. a D2
receptor homodimer apo form,
monomer contributing TM4–
TM5 to the interface. b D2
receptor homodimer in complex
with 5j, monomer contributing
TM4–TM5 to the interface. c D2
receptor homodimer apo form,
monomer contributing TM7–
TM1 to the interface. d D2
receptor homodimer in complex
with 5j, monomer contributing
TM7–TM1 to the interface
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left part of Fig. 12), it was observed that the part of TM5 close
to the extracellular end approaches TM6 which in turn brings
TM7 closer to the dimer in complex with the bivalent ligand
compared to dimer apo form. Regarding the monomer that
supplies TM4–TM5 to the interface, the greatest change was
found for the TM3 part close to the extracellular end that
points to TM2 in the dimer in complex with the bivalent li-
gand compared to the dimer apo form. The detailed analysis of
the conformational changes in the dimer will be the subject of
future studies. Concerning conformational changes of the bi-
valent ligands, in the case of a ligand, such as 5j, interacting
with both orthosteric sites, the ligand interacts stably with both
Asp 3.32 and its linker, and its spacer parts possess a relatively
greater conformational freedom, which contributes signifi-
cantly to ligand RMSD (data not shown).
Conclusions
In this work, we modeled the dopamine D2 receptor dimer in
the inactive conformation using our previously elaborated
multi-component protein–protein docking-based protocol.
We found that the best scored dimer model has the TM4–
TM5–TM7–TM1 interface, which is in agreement with exper-
imental data [42, 43].We used this model to study interactions
of five sets of bivalent antagonists with the D2 receptor homo-
dimer. We found that bivalent antagonists stabilize the recep-
tor inactive conformation by maintaining the ionic lock inter-
action, and change the dimer interface by breaking a set of
hydrogen bonds and maintaining another set of hydrogen
bonds that are water- and ligand-mediated in the extracellular
and intracellular part of the interface, respectively.
The docking study of ligands 1a–1f, 2a–2 g, 3a–3 g, 4a–4i
and 5a–5n into our dopamine D2 homodimer model revealed
that most of the compounds tested are not able to interact at
both orthosteric sites simultaneously. We determined a
bitopic, orthosteric-allosteric type of interaction within one
monomer for the smallest ligands, and the two monomers
for medium-size ligands; only ligands 5j–5n were able to
interact in purely homobivalent conformation. Therefore, our
work implies that it might be worth considering incorporating
an allosteric pharmacophore into ligands with similar linker
length (bitopic ligand) for the future design of ligands
targeting the D2 receptor homodimer as well as other family
A GPCRs homo- and heterodimers. In contrast, we deter-
mined the possibility that larger ligands may interaction with
two orthosteric sites of a D2 homodimer; as a result, similar
linker lengths should be considered for ligands with two
orthosteric pharmacophores (homo- or heterobivalent
ligands).
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